Oxytocin May be Superior to Gliptins as a Potential Treatment for Diabetic COVID-19 Patients
Downloads
Diabetes is a comorbidity associated with an increased risk of severe COVID-19. Gliptins are anti-diabetic drugs that inhibit dipeptidyl peptidase-4 (DPP4) and they have been proposed as a possible treatment for COVID-19 patients with and without diabetes due to their immunomodulatory properties. Oxytocin has also been proposed as a treatment for COVID-19 due to its immunomodulatory properties as well as other mechanisms. In addition, oxytocin has been identified as a natural DPP4 inhibitor. Therefore, oxytocin not only has the properties associated with DPP4 inhibition but it has numerous additional beneficial properties. It is proposed that oxytocin may be superior to DPP4 inhibitors for COVID-19 patients especially for patients with type 2 diabetes.
Doi: 10.28991/SciMedJ-2020-02-SI-10
Full Text: PDF
Solerte, S. B., Di Sabatino, A., Galli, M., & Fiorina, P. (2020). Dipeptidyl peptidase-4 (DPP4) inhibition in COVID-19. Acta Diabetologica, 57(7), 779–783. doi:10.1007/s00592-020-01539-z.
Bassendine, M. F., Bridge, S. H., McCaughan, G. W., & Gorrell, M. D. (2020). COVID‐19 and comorbidities: A role for dipep-tidyl peptidase 4 (DPP4) in disease severity? Journal of Diabetes, 12(9), 649–658. doi:10.1111/1753-0407.13052.
Iacobellis, G. (2020). COVID-19 and diabetes: Can DPP4 inhibition play a role? Diabetes Research and Clinical Practice, 162, 108125. doi:10.1016/j.diabres.2020.108125.
Rao, P. P. N., Pham, A. T., Shakeri, A., Shatshat, A. E., Zhao, Y., Karuturi, R. C., & Hefny, A. A. (2020). Drug repurposing: Dipeptidyl peptidase IV (DPP4) inhibitors as potential agents to treat SARS-CoV-2 (2019-nCov) infection. doi:10.21203/rs.3.rs-28134/v1.
Chittepu, V. C. S. R., Kalhotra, P., Osorio-Gallardo, T., Jiménez-Martínez, C., Robles-de la Torre, R. R., Gallardo-Velazquez, T., & Osorio-Revilla, G. (2019). New Molecular Insights into the Inhibition of Dipeptidyl Peptidase-4 by Natural Cyclic Peptide Oxyto-cin. Molecules, 24(21), 3887. doi:10.3390/molecules24213887.
Elabd, S., & Sabry, I. (2015). Two Birds with One Stone: Possible Dual-Role of Oxytocin in the Treatment of Diabetes and Oste-oporosis. Frontiers in Endocrinology, 6. doi:10.3389/fendo.2015.00121.
Qian, W., Zhu, T., Tang, B., Yu, S., Hu, H., Sun, W., Pan, R., Wang, J., Wang, D., Yang, L., Mao, C., Zhou, L., & Yuan, G. (2014). Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients. The Journal of clinical endo-crinology and metabolism, 99(12), 4683–4689. doi:10.1210/jc.2014-2206.
Buemann, B., Marazziti, D., & Uvnäs-Moberg, K. (2020). Can intravenous oxytocin infusion counteract hyperinflammation in COVID-19 infected patients? The World Journal of Biological Psychiatry, 1–30. doi:10.1080/15622975.2020.1814408.
Imami, A. S., O'Donovan, S. M., Creeden, J. F., Wu, X., Eby, H., McCullumsmith, C. B., Uvnäs-Moberg, K., McCullumsmith, R. E., & Andari, E. (2020). Oxytocin's Anti-inflammatory and Pro-immune functions in COVID-19: A Transcriptomic Signature Based Approach. Physiological genomics, 10.1152/physiolgenomics.00095.2020. Advance online publication. doi:10.1152/physiolgenomics.00095.2020.
Soumier, A., & Sirigu, A. (2020). Oxytocin as a potential defence against Covid-19? Medical Hypotheses, 140, 109785. doi:10.1016/j.mehy.2020.109785.
Diep, P. T., Buemann, B., Uvnäs-Moberg, K., & Marazziti, D. (2020). Oxytocin, a possible treatment for COVID-19? Every-thing to gain, nothing to lose. Clinical Neuropsychiatry, 17(3). doi:10.36131/CNEPUB20201703.
Viero, C., Shibuya, I., Kitamura, N., Verkhratsky, A., Fujihara, H., Katoh, A., Ueta, Y., Zingg, H. H., Chvatal, A., Sykova, E., & Dayanithi, G. (2010). REVIEW: Oxytocin: Crossing the bridge between basic science and pharmacotherapy. CNS neuroscience & therapeutics, 16(5), e138–e156. doi:10.1111/j.1755-5949.2010.00185.x.
- This work (including HTML and PDF Files) is licensed under a Creative Commons Attribution 4.0 International License.
